Home Prevalence and association of sIgA in saliva and Pseudomonas aeruginosa infection in TB patients: a cross-sectional study
Article Open Access

Prevalence and association of sIgA in saliva and Pseudomonas aeruginosa infection in TB patients: a cross-sectional study

  • Keqiang Wan ORCID logo , Chang Su ORCID logo , Fang Yin ORCID logo and Caoyuan Yao ORCID logo EMAIL logo
Published/Copyright: August 31, 2023

Abstract

Objectives

Pseudomonas aeruginosa is pathogenic in immunocompromised individuals. It has several complex mechanisms for evading human immunity. The objective of the study was to examine the secretory immunoglobulin A (sIgA) mediated immune response in saliva to detect P. aeruginosa in pulmonary tuberculosis.

Methods

The infection with P. aeruginosa was categorized according to the Leeds criteria in the final 86 individuals who were proven to have pulmonary tuberculosis by polymerase chain reaction. Levels of serum immunoglobulin G (IgG) and sIgA which are specific to P. aeruginosa were measured using the method of ELISA.

Results

Patients in the “free of infection (patients who were infected with P. aeruginosa in the lower respiratory tract at the beginning of the study later became negative)” and “intermittent colonized (patients who were infected with P. aeruginosa throughout the study)” groups had substantially higher median baseline sIgA levels in saliva and a much greater proportion of sIgA positive than patients who were never colonized (patients who were found to be P. aeruginosa negative throughout the study) (p=0.038). Median baseline IgG level was 10.7 (1.7–145.0), 8.3 (2.5–22.9), and 6.7 (3.3–17.1) for the patients categorized as “intermittent colonization”, “free of infection” and “never colonized”, respectively. After 3 years of study, sIgA level was found in significant high level among the patients with infection of P. aeruginosa (p=0.003).

Conclusions

Secretory IgA may be readily collected from saliva and is a useful diagnostic technique for determining whether P. aeruginosa infection has occurred.

Introduction

A variety of bacteria present in lungs of patients infected with pulmonary tuberculosis [1]. Frequently isolated and potentially pathogenic microorganisms in pulmonary tuberculosis include H. influenza, Pseudomonas aeruginosa, and Streptococcus pneumonia. In pulmonary tuberculosis, P. aeruginosa is associated with reduced lung function and higher mortality [1, 2]. Some studies have reported a possible association between the presence of these respiratory microorganisms and poorer prognosis in pulmonary tuberculosis [3]. P. aeruginosa has several complex mechanisms for evading human immunity, one of which is the formation of a biofilm that protects the bacterial cell from phagocytosis by human immune cells while also protecting the bacterial cell from antibacterial medications. P. aeruginosa can produce rhamnolipids to kill human Poly Morpho Nuclear (PMN) leukocytes, macrophages, and erythrocytes. It has been shown that immunocompromised individuals, like patients of pulmonary tuberculosis are associated with several intrinsic loopholes in immune mechanisms, which may include a defect in mucociliary clearance, and dysregulation of immune and inflammatory mechanisms [4]. The published reports [5], [6], [7] show that the other bacterial infections are more dominant and P. aeruginosa is not the dominant co-infection in pulmonary tuberculosis. However, P. aeruginosa is the most frequently isolated bacteria among pulmonary tuberculosis [5]. Therefore, it is required to study co-infection with P. aeruginosa in pulmonary tuberculosis.

The immune mechanism usually found against the infection of P. aeruginosa includes responses by epithelial cells, T-cells, recruited neutrophils, Type-I interferon-mediated innate immunity, etc. [8]. Other mechanisms include activation of NF-κB-mediated proinflammatory chemokines and cytokines and activation of inflammasomes signaling. Production and release of IL (interleukin)-1β and IL-18 primarily from the alveolar macrophages (stimulated by the flagellar antigens of P. aeruginosa) results in clearance of bacterial invasion. But the disadvantage of this production is that both IL-1β and IL-18 play a role in increasing cytotoxicity in the lung and thus increasing mortality [9]. In patients with pulmonary tuberculosis, P. aeruginosa causing lung infection is found to grow in places where oxygen is deficient, like mucus plugs from the lower respiratory tract of the patients [10]. This is found that P. aeruginosa is prone to be present in oxygen-deficient areas which favors them to have biofilm formation around them under an anaerobic environment [11, 12].

To test P. aeruginosa infection, ELISA can be done to measure the specific IgG against the bacterium. Antibodies may be found in the upper airways, tears, and saliva, all of which can be readily retrieved from the patient for diagnosis. Secretory immunoglobulin A (sIgA) is easily detected from saliva in patients with chronic lung infection with P. aeruginosa. It has been well noted that the diagnostic value of sIgA obtained from saliva is significant [13].

The objective of the study was the early detection of P. aeruginosa in pulmonary tuberculosis patients by assessing the secretory IgA-mediated immune response in saliva.

Materials and methods

Ethics approval and consent to participate

The study by approved by the YongChuan Hospital of Chongqing Medical University ethical and research board. The study reporting adheres to the law of China and the V2008 Declarations of Helsinki. All participants or their legally authorized persons signed an informed consent form regarding diagnosis, pathology, and publication of the patients’ personal information in the article form.

Study population

The range of age of the patients varies between 30 and 45 years of age. The present cross-sectional study was done with 86 patients who had pulmonary tuberculosis. Although 102 pulmonary tuberculosis patients were selected initially, 16 patients were excluded or did not show interest as a volunteer.

Diagnosis of pulmonary tuberculosis

The diagnosis of pulmonary tuberculosis was established using chest X-ray, sputum microscopy, culture in both liquid and solid media, and nucleic acid amplification, polymerase chain reaction. Chest computed tomography, and histopathological examination of biopsy samples have also been done in patients with smear-negative pulmonary tuberculosis and drug-resistant tuberculosis patients. A 165 bp was targeted for “nucleic acid amplification” and “polymerase chain reaction.

P. aeruginosa classification

P. aeruginosa was classified according to Leeds criteria as follows [14]:

  1. Patients who never had P. aeruginosa infection confirmed from the microbiological culture with negative screening serum Ig G result (P1)

  2. Patients who had P. aeruginosa infection confirmed in microbiological culture, but the patients are free from P. aeruginosa infection 12 months from the present study (P2)

  3. Patients from whom P. aeruginosa could be isolated from less than 50 % of cultures in the last 12 months with serum Ig G negative or P. aeruginosa was isolated with serum Ig G positive (P3).

Pus was the clinical sample used for microbiological culture. These were inoculated on Mac Conkey agar at 37 °C for 48 h. Standard microbiological techniques were used for interpretation [15].

ELISA test

The pad was brushed briefly on the lower gums and then held between the gum and the cheek for 3 min. Levels of serum Ig G and sIgA, which are specific to P. aeruginosa are measured using the method of ELISA (NIF-1: Cusabio Biotech CO. LTD, Wuhan, Hubei Province 430206, P.R. China (Catalogue no. CSB-EL026683HU); analytical measuring range: 80–120 %). Antichlamydial antibody linked with enzyme was added. Substrate color was then measured by an ELISA reader. The intensity of the color was directly proportional to the concentration of antigen present in the specimen. A 96-well ELISA plate was used to measure the levels. A horseradish peroxidase (HRP) conjugated polyclonal rabbit anti-human Ig G and sIgA was added. Ig G was added for measuring antibodies in serum, while sIgA was added to measure antibodies in saliva. The saliva samples were collected for one time and Ig G and sIgA were measured one time in patients. One time collect sputum cultures for P. aeruginosa from patients.

Various scenarios of patients

The change in the level of sIgA in saliva was correlated with the status of P. aeruginosa in the lower respiratory tract based on the levels and their increase as the severity of the disease increased. The status of P. aeruginosa was considered in terms of microbiological and serological results of P. aeruginosa. The changes in the status of sIgA were noted periodically. The analysis of sIgA and the status of P. aeruginosa in the lower respiratory tract were made in various scenarios.

In the first scenario, for study the patients effectively, they were divided into 3 groups (a) never colonized, (b) free of infection, (c) intermittent colonized: firstly, patients found to be P. aeruginosa negative throughout the study or they never encountered P. aeruginosa infection (categorized as “never colonized”). Secondly, patients who were infected with P. aeruginosa in the lower respiratory tract at the beginning of the study later became negative (categorized as “free of infection”). Thirdly, patients infected with P. aeruginosa throughout the study (categorized as “intermittent colonized”).

In the second scenario, the patients who became P. aeruginosa negative later during the study were analyzed to observe any change in the level of sIgA. For this purpose, the patients were divided into 2 groups as follows: firstly, the patients who had ≥1 positive result of P. aeruginosa (in microbiological culture) or serum IgG, and secondly, the patients who never had any positive result of culture or presence of specific serum IgG.

In the third scenario, the patients were classified based on their history of exposure to P. aeruginosa in the lower respiratory tract. Even with a single occurrence of P. aeruginosa colonization, the history of the patient was positive in this scenario. The patients who never showed any sign of exposure in terms of positive culture or serum IgG level were considered to have no history of exposure to P. aeruginosa.

Statistical analysis

The linearity of continuous parameters was evaluated using the method of Kolmogorov and Smirnov. According to the scenarios, sIgA serum levels and the status of P. aeruginosa were compared. The non-parametric Mann-Whitney U test (for two independent samples) and one-way Kruskal-Wallis’ test (for more than two independent samples) were employed for comparison. Using the Wilcoxon test (for two different periods) and the Friedman test (for more than two different periods), the assessment of sIgA level variation was well analyzed. Differences in the percentages are assessed by employing the Chi-square test. Odd-ratio and 95 % confidence intervals were analyzed by using SPPS 20.0 software and a p-value less than 0.05 was statistically significant for all the tests.

Results

Study population

Out of 86 patients, 46 (53 %) were female patients, while the number of males was 40 (47 %). The median age of the patients was 38.1±1.6 years. Sputum was obtained from 25 (29 %) patients, while respiratory swabs were obtained from the rest of them (61 (71 %) patients).

The patients who were “free of infection” showed the following outcomes: out of 26 such patients (as shown in Table 1), 8 patients became intermittent colonization (sIgA positive) while 4 patients turned into chronic cases (sIgA negative). The rest of the 14 patients (out of 26 patients) remained free of infection. Five of the 14 individuals were positive for sIgA, whereas the others tested negative (Figure 1).

Table 1:

Status of patients during the time of enrollment.

Status of Pseudomonas aeruginosa Intermittent colonized Free of infection Never colonized Comparisons
n 37 26 23 p-Value
Gender, M/F 12/25 12/14 16/7 0.0196 (χ 2-test)
Age, years 39 (31–45) 35 (32–41) 35.2 (33–39) 0.058 (Kruskal-Wallis’ test)
Serum IgG, U/mL 10.7 (1.7–145.0) 8.3 (2.5–22.9) 6.7 (3.3–17.1) 0.295 (Kruskal-Wallis’ test)
sIgA, U/mL 25.3 (3.6–427.5) 39.4 (3.2–223.1) 16.4 (2.5–41.2) 0.038 (Kruskal-Wallis’ test)
% Secretory immunoglobulin A positivity 45.0 36.0 0.0 0.003 (Kruskal-Wallis’ test)
  1. M, male; F, female; IgG, serum immunoglobulin G; sIgA, secretory immunoglobulin A. Variables presented as median (Q1–Q3). A p-value <0.05 is considered significant.

Figure 1: 
Patients who were “free of infection” at the start of the study and their outcome after the follow-up.
Figure 1:

Patients who were “free of infection” at the start of the study and their outcome after the follow-up.

Next, 23 patients were classified as “never colonized”. Out of 23 patients, 11 patients were colonized by P. aeruginosa during the study. This group of patients who got colonized during the study had different outcomes finally. Out of the 6 patients who got free from the colonization, 4 showed sIgA negative while 2 showed sIgA positive. Again, out of 11 patients who were categorized as “colonized during the study”, the remaining 5 patients were categorized as “intermittent colonization”. Of these 5 patients, 3 were sIgA positive while 2 were sIgA negative.

Again, out of 23 patients who belonged to the “never colonized” group, the remaining 12 patients remained as it is. But out of 12 patients, 9 showed sIgA negative while 3 were sIgA positive (Figure 2).

Figure 2: 
Patients who were “never colonized” at the start of the study and their outcome during the study and after the follow-up.
Figure 2:

Patients who were “never colonized” at the start of the study and their outcome during the study and after the follow-up.

Again, 37 patients were categorized as “intermittent colonized”, out of which, 14 patients remained colonized at the end of the study. Out of 8 patients who became chronic cases, 4 showed sIgA negative, while another 4 showed sIgA positive. Out of 14 patients who remained as colonized, 5 patients were sIgA positive, while 9 patients were found to be sIgA negative. Out of 15 patients who became free of colonization later, 9 patients were found to be sIgA positive while 6 patients were found to be sIgA negative (Figure 3).

Figure 3: 
Patients who were “intermittently colonized” at the start of the study and their outcome during the study and after the follow-up.
Figure 3:

Patients who were “intermittently colonized” at the start of the study and their outcome during the study and after the follow-up.

First scenario

Median baseline IgG level was 10.7 U/mL (1.7–145.0), 8.3 (2.5–22.9), 6.7 (3.3–17.1) for the patients categorized as “intermittent colonization”, “free of infection” and “never colonized”, respectively. After 3 years of study, sIgA level was found to significantly decrease levels among the patients with infection of P. aeruginosa. The level of sIgA increased prominently among patients who were positive for P. aeruginosa infection and those who had the infection but later became negative.

Second scenario

The patients who became P. aeruginosa negative later during the study were analyzed to observe any change in the level of sIgA. In the second scenario, the median sIgA was 26.3 U/mL, which had P. aeruginosa recurrence, while the patients who had no recurrence, showed lesser median sIgA, that is, 23.3 U/mL. The level of median sIgA increased with time, increasing up to 98.3 U/mL in the second year for those who had a recurrence, followed by 74.1 U/mL in the third year. The patients who had no recurrence also showed increased median sIgA levels up to the second year; in the third year, the median sIgA level came much lower (Table 2).

Table 2:

Status of patients during the second scenario.

Pseudomonas aeruginosa recurrence Yes No p-Value between yes and no
sIgA baseline (U/mL, n=86) 26.3 (2.9–229.1) 23.3 (3.6–427.1) 0.280 (Mann-Whitney U test)
sIgA year 1 (U/mL, n=86) 56.1 (7.1–342.1) 23.7 (6.5–279) 0.013 (Mann-Whitney U test)
sIgA year 2 (U/mL, n=86) 98.3 (12–707.21) 41.2 (14.8–606.5) 0.259 (Mann-Whitney U test)
sIgA year 3 (U/mL, n=86) 74.1 (9.2–684.5) 29.4 (11.1–286.7) 0.117 (Mann-Whitney U test)
p-value among different time periods 0.003 (Kruskal-Wallis’ test) < 0.001 (Kruskal-Wallis’ test)
  1. sIgA, secretory immunoglobulin A. Variables presented as median (Q1–Q3), A p-value <0.05 is considered significant.

Third scenario

The patients were classified based on their history of exposure to P. aeruginosa in the lower respiratory tract. The secretory IgA positivity in the third year was 48.1 % among the exposed group. Interestingly, the percentage of secretory IgA positivity came down to 21.9 U/mL among the non-exposed group as compared to 29.6 % in the second year. This shows that in the non-exposed patients who did not get P. aeruginosa infection despite the presence of sIgA in the second year and made up to the third year, the risk of getting P. aeruginosa infection lowered among them (Table 3).

Table 3:

Exposure of Pseudomonas aeruginosa during follow-up study and corresponding changes of sIgA positivity percent and its level in saliva.

History of Pseudomonas aeruginosa exposure Exposed Non-exposed
Baseline

N 63 23
%sIgA positivity 41.5 0.0
sIgA, U/mL 33.35 (3.2–427.5) 16.4 (2.5–41.2)

Year 1

N 65 21
%sIgA positivity 46.3 9.5
sIgA, U/mL 46.4 (4.2–410.4) 21.2 (5.5–91.2)

Year 2

N 68 18
%sIgA positivity 47.2 29.6
sIgA, U/mL 52.2 (11.2–612.7) 45.9 (17.2–321.1)

Year 3

N 72 14
%sIgA positivity 48.1 21.9
sIgA, U/mL 51.35 (11.6–551.5) 26.4 (18.2–115.3)
  1. sIgA, secretory immunoglobulin A. Variables presented as median (Q1–Q3).

Discussion

This study presents an association between the detection of P. aeruginosa in chronic lung infection and sIgA in the saliva. It is a non-invasive method and so it has high patient compliance. Secondly, it has been found that P. aeruginosa-specific sIgA response in the saliva is significant even when there is no significant P. aeruginosa culture in samples obtained from the lower respiratory tract [16]. The results of an association between the detection of P. aeruginosa in pulmonary tuberculosis of adult patients and sIgA in the saliva of the current study are consistent with those of a prospective study of pediatric cystic fibrosis patients [17]. Using saliva to determine P. aeruginosa infection is advantageous in many ways.

In most cases, this organism is found both in the lower and upper respiratory tract. It was also found that P. aeruginosa can be present in both the upper and lower respiratory tract. It is hypothesized that P. aeruginosa first colonizes the upper respiratory tract and then proceeds to the lungs [18]. It can be used as an early detection method of P. aeruginosa infection in the respiratory tract. Therefore, sIgA obtained from saliva specific to P. aeruginosa can ease the management of P. aeruginosa by showing an increased risk of P. aeruginosa infection [19, 20]. Early management of pseudomonal treatment is very important. It was found that early strong antimicrobials can reduce pseudomonal colonization among patients [21]. Using sIgA detection, it is possible to detect P. aeruginosa in the early stage.

The usage of three scenarios implied the significance of the determination of sIgA level in these patients to detect P. aeruginosa early. Other studies showed that there is a chance that 42 % of patients may contain the same pathogens in the lower respiratory tract who are yet to undergo transplantation and who has already done transplantation [22].

It cannot be said with full evidence that P. aeruginosa can be attributed to the presence of sIgA obtained from saliva, but some occurrences suggest high genotype similarity between samples of the upper and lower respiratory tract [23]. In a way, it confirms that paranasal sinuses may act as reservoirs for bacteria [24, 25].

There are limitations of this study to consider. The number of patients was unsatisfactory and it would be better if more patients were there. More patients might have given a more statistically significant result. Also, the salivary sIgA response was not compared with the overall microbiological assessment of the sinuses. Another limitation is that this present study does not provide the long-term outcomes of P. aeruginosa infection and lower respiratory tract infection.

Conclusions

The research was carried out over three years, and there is sufficient evidence to conclude that the detection of secretory immunoglobulin A in saliva may be attributed to increased risk or P. aeruginosa infection. Secretory immunoglobulin A is relatively easy to obtain from the saliva and is an effective diagnostic technique for determining whether a person has been infected with P. aeruginosa. As a result of this finding, it is possible to commence early intervention.


Corresponding author: Caoyuan Yao, Department of Respiratory and Critical Care Medicine, YongChuan Hospital of Chongqing Medical University, No. 439 Xuanhua Road, Yongchuan District, Chongqing, 402160, China, Phone/Fax: 0086-13648314471, E-mail:

Acknowledgments

The authors are thankful for the medical and non-medical staff of the YongChuan Hospital of Chongqing Medical University, Chongqing, China.

  1. Research ethics: The study by approved by the YongChuan Hospital of Chongqing Medical University ethical and research board under vide letter no. YCCMU/2018/In-47.

  2. Informed consent: Informed consent was obtained from all individuals included in this study.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Competing interests: Authors state no conflict of interest.

  5. Research funding: None declared.

References

1. Kim, SB, Lee, WY, Lee, JH, Lee, SJ, Lee, MK, Kim, SH, et al.. A variety of bacterial aetiologies in the lower respiratory tract at patients with endobronchial tuberculosis. PLoS One 2020;15:e0234558. https://doi.org/10.1371/journal.pone.0234558.Search in Google Scholar PubMed PubMed Central

2. Chandrasekaran, R, Mac Aogáin, M, Chalmers, JD, Elborn, SJ, Chotirmall, SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med 2018;18:83. https://doi.org/10.1186/s12890-018-0638-0.Search in Google Scholar PubMed PubMed Central

3. Ravimohan, S, Kornfeld, H, Weissman, D, Bisson, GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev 2018;27:170077. https://doi.org/10.1183/16000617.0077-2017.Search in Google Scholar PubMed PubMed Central

4. Chen, K, Kolls, JK. T cell-mediated host immune defenses in the lung. Annu Rev Immunol 2013;31:605–33. https://doi.org/10.1146/annurev-immunol-032712-100019.Search in Google Scholar PubMed PubMed Central

5. Regmi, RS, Khadka, S, Sapkota, S, Adhikari, S, Dhakal, KK, Dhakal, B, et al.. Bacterial etiology of sputum from tuberculosis suspected patients and antibiogram of the isolates. BMC Res Notes 2020;13:520. https://doi.org/10.1186/s13104-020-05369-8.Search in Google Scholar PubMed PubMed Central

6. Iliyasu, G, Mohammad, AB, Yakasai, AM, Dayyab, FM, Oduh, J, Habib, AG. Gram-negative bacilli are a major cause of secondary pneumonia in patients with pulmonary tuberculosis: evidence from a cross-sectional study in a tertiary hospital in Nigeria. Trans R Soc Trop Med Hyg 2018;12:252–4. https://doi.org/10.1093/trstmh/try044.Search in Google Scholar PubMed

7. Attia, EF, Pho, Y, Nhem, S, Sok, C, By, B, Phann, D, et al.. Tuberculosis and other bacterial co-infection in Cambodia: a single center retrospective cross-sectional study. BMC Pulm Med 2019;19:60. https://doi.org/10.1186/s12890-019-0828-4.Search in Google Scholar PubMed PubMed Central

8. Tao, J, Zhou, X, Jiang, Z. The three musketeers of cytosolic DNA sensing and signaling. IUBMB Life 2016;68:858–70. https://doi.org/10.1002/iub.1566.Search in Google Scholar PubMed

9. Kim, SB, Lee, WY, Lee, JH, Lee, SJ, Lee, MK, Kim, SH, et al.. A variety of bacterial aetiologies in the lower respiratory tract at patients with endobronchial tuberculosis. PLoS One 2020;15:e0234558. https://doi.org/10.1371/journal.pone.0234558.Search in Google Scholar

10. Turcios, NL. Cystic fibrosis lung disease: an overview. Respir Care 2020;65:233–51. https://doi.org/10.4187/respcare.06697.Search in Google Scholar PubMed

11. Filiatrault, MJ, Picardo, KF, Ngai, H, Passador, L, Iglewski, BH. Identification of Pseudomonas aeruginosa genes involved in virulence and anaerobic growth. Infect Immun 2006;74:4237–45. https://doi.org/10.1128/iai.02014-05.Search in Google Scholar PubMed PubMed Central

12. Kicic, A, de Jong, E, Ling, KM, Nichol, K, Anderson, D, Wark, PAB, et al.. Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium. J Allergy Clin Immunol 2020;145:1562–73. https://doi.org/10.1016/j.jaci.2020.02.018.Search in Google Scholar PubMed

13. Aanaes, K, Johansen, HK, Poulsen, SS, Pressler, T, Buchwald, C, Høiby, N. Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros 2013;12:81–7. https://doi.org/10.1016/j.jcf.2012.07.001.Search in Google Scholar PubMed

14. Hoo, ZH, Hitchcock, L, Curley, R, Wildman, MJ. A comparison of the CFHH criteria against the Leeds criteria in determining the Pseudomonas aeruginosa status among adults with cystic fibrosis. Respir Med 2020;171:106103. https://doi.org/10.1016/j.rmed.2020.106103.Search in Google Scholar PubMed

15. Maharjan, N. Pseudomonas aeruginosa isolates among clinical samples showing growth in a tertiary care centre: a descriptive cross-sectional study. J Nepal Med Assoc JNMA 2022;60:676–80. https://doi.org/10.31729/jnma.6517.Search in Google Scholar PubMed PubMed Central

16. Mauch, RM, Rossi, CL, Aiello, TB, Ribeiro, JD, Ribeiro, AF, Høiby, N, et al.. Secretory IgA response against Pseudomonas aeruginosa in the upper airways and the link with chronic lung infection in cystic fibrosis. Pathog Dis 2017;75:1–4. https://doi.org/10.1093/femspd/ftx069.Search in Google Scholar PubMed

17. Mauch, RM, Rossi, CL, Nolasco da Silva, MT, Bianchi Aiello, T, Ribeiro, JD, Ribeiro, AF, et al.. Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients. Med Microbiol Immunol 2019;28:205–13. https://doi.org/10.1007/s00430-019-00578-w.Search in Google Scholar PubMed

18. Bonestroo, HJ, de Winter-de Groot, KM, van der Ent, CK, Arets, HG. Upper and lower airway cultures in children with cystic fibrosis: do not neglect the upper airways. J Cyst Fibros 2010;9:130–4. https://doi.org/10.1016/j.jcf.2010.01.001.Search in Google Scholar PubMed

19. Illing, EA, Woodworth, BA. Management of the upper airway in cystic fibrosis. Curr Opin Pulm Med 2014;20:623–31. https://doi.org/10.1097/mcp.0000000000000107.Search in Google Scholar PubMed PubMed Central

20. Aanæs, K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J Cyst Fibros 2013;12:S1–20. https://doi.org/10.1016/s1569-1993(13)00150-1.Search in Google Scholar

21. Ramsay, KA, Sandhu, H, Geake, JB, Ballard, E, O’Rourke, P, Wainwright, CE, et al.. The changing prevalence of pulmonary infection in adults with cystic fibrosis: a longitudinal analysis. J Cyst Fibros 2017;16:70–7. https://doi.org/10.1016/j.jcf.2016.07.010.Search in Google Scholar

22. Morlacchi, LC, Greer, M, Tudorache, I, Blasi, F, Welte, T, Haverich, A, et al.. The burden of sinus disease in cystic fibrosis lung transplant recipients. Transpl Infect Dis 2018;20:e12924. https://doi.org/10.1111/tid.12924.Search in Google Scholar

23. Ahmed, B, Bush, A, Davies, JC. How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis. Arch Dis Child Educ Pract 2014;99:181–7. https://doi.org/10.1136/archdischild-2012-303408.Search in Google Scholar

24. Mainz, JG, Naehrlich, L, Schien, M, Käding, M, Schiller, I, Mayr, S, et al.. Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax 2009;64:535–40. https://doi.org/10.1136/thx.2008.104711.Search in Google Scholar

25. Ciofu, O, Johansen, HK, Aanaes, K, Wassermann, T, Alhede, M, von Buchwald, C, et al.. P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. J Cyst Fibros 2013;12:729–36. https://doi.org/10.1016/j.jcf.2013.02.004.Search in Google Scholar

Received: 2023-02-26
Accepted: 2023-06-06
Published Online: 2023-08-31

© 2023 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Exploring nanotechnology-based approaches using miRNAs to treat neurodegenerative disorders
  4. Research Articles
  5. Rhesus factor is a stronger predictor for the risk of Sars-CoV-2 and mortality than ABO blood types
  6. Clinical laboratory testing in the emergency department: a six-year analysis
  7. New data for endemic Phlomis brevibracteata Turrill from North Cyprus: biological activities and chemical composition
  8. Inhibitory effect of organic acids on human neutrophil myeloperoxidase’s peroxidation, chlorination, and nitration activities
  9. Prevalence and association of sIgA in saliva and Pseudomonas aeruginosa infection in TB patients: a cross-sectional study
  10. Within- and between-subject biological variation of hemostasis parameters in a study of 26 healthy individuals
  11. Nasal fluid sample as a reliable matrix for determination of cytokine levels in childhood asthma
  12. Evaluation of the monocyte-to-lymphocyte ratio (MLR) and C-reactive protein (CRP) as diagnostic biomarkers in different lung diseases, especially for SCLC
  13. The association between plasma concentration of pigment epithelium-derived factor and diabetic retinopathy
  14. Can preoperative neopterin levels predict acute kidney injury in patients undergoing on-pump cardiac surgery?
  15. Exosomal prognostic biomarkers predict metastatic progression and survival in breast cancer patients
  16. miR-145-5p suppresses cell proliferation by targeting IGF1R and NRAS genes in multiple myeloma cells
  17. miR-564 and miR-718 expressions are downregulated in colorectal cancer tissues
  18. Ischemic cerebrovascular disease caused by genetic mutation and patent foramen ovale
  19. Comprehensive geriatric assessment and drug burden in elderly chronic kidney disease patients
  20. Exploring the enzyme inhibitory properties of Antarctic algal extracts
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/tjb-2023-0046/html
Scroll to top button